|
1
|
Alberú J: Clinical insights for cancer
outcomes in renal transplant patients. Transplant Proc. 42(9
Suppl): S36–S40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Briggs JD: Causes of death after renal
transplantation. Nephrol Dial Transplant. 16:1545–1549. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kasiske BL, Snyder JJ, Gilbertson DT and
Wang C: Cancer after kidney transplantation in the United States.
Am J Transplant. 4:905–913. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
First MR and Peddi VR: Malignancies
complicating organ transplantation. Transplant Proc. 30:2768–2770.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maser RS and DePinho RA: Connecting
chromosomes, crisis and cancer. Science. 297:565–569. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheung AL and Deng W: Telomere
dysfunction, genome instability and cancer. Front Biosci.
13:2075–2090. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grady WM: Genomic instability and colon
cancer. Cancer Metastasis Rev. 23:11–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Lange T: Shelterin: The protein complex
that shapes and safeguards human telomeres. Genes Dev.
19:2100–2110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martínez P and Blasco MA: Role of
shelterin in cancer and aging. Aging Cell. 9:653–666. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu W, Zhang Y, Liu D, Songyang Z and Wan
M: Telomeres-structure, function and regulation. Exp Cell Res.
319:133–141. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Artandi SE and DePinho RA: Telomeres and
telomerase in cancer. Carcinogenesis. 31:9–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong CM, Lee XW and Wang X: Telomere
shortening in human diseases. Febs J. 280:3180–3193. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DePinho RA and Polyak K: Cancer
chromosomes in crisis. Nat Genet. 36:932–934. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harley CB, Futcher AB and Greider CW:
Telomeres shorten during ageing of human fibroblasts. Nature.
345:458–460. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wenz C, Enenkel B, Amacker M, Kelleher C,
Damm K and Lingner J: Human telomerase contains two cooperating
telomerase RNA molecules. Embo J. 20:3526–3534. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mergny JL, Riou JF, Mailliet P,
Teulade-Fichou MP and Gilson E: Natural and pharmacological
regulation of telomerase. Nucleic Acids Res. 30:839–865. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim NW, Piatyszek MA, Prowse KR, et al:
Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hiyama E and Hiyama K: Telomerase as tumor
marker. Cancer Lett. 194:221–233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calado R and Young N: Telomeres in
disease. F1000 Med Rep. 4:82012.PubMed/NCBI
|
|
21
|
Witkowska A, Gumprecht J, Glogowska-Ligus
J, et al: Expression profile of significant immortalization genes
in colon cancer. Int J Mol Med. 25:321–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rostkowska-Nadolska B, Kapral M, Fraczek
M, Kowalczyk M, Gawron W and Mazurek U: Transcriptional activity of
genes-encoding kinin B1 and B2 receptors and kinin-dependent genes
in nasal polyps. Adv Med Sci. 54:211–220. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strzalka-Mrozik B, Stanik-Walentek A,
Kapral M, et al: Differential expression of transforming growth
factor-beta isoforms in bullous keratopathy corneas. Mol Vis.
16:161–166. 2010.PubMed/NCBI
|
|
24
|
Berezowski P, Strzalka-Mrozik B,
Forminska-Kapuscik M, et al: Posttraumatic temporal TGF-beta mRNA
expression in lens epithelial cells of paediatric patients. Folia
Biol (Praha). 58:24–29. 2012.PubMed/NCBI
|
|
25
|
Kapral M, Wawszczyk J, Jurzak M, Hollek A
and Weglarz L: The effect of inositol hexaphosphate on the
expression of selected metalloproteinases and their tissue
inhibitors in IL-1β-stimulated colon cancer cells. Int J Colorectal
Dis. 27:1419–1428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen LY, Liu D and Songyang Z: Telomere
maintenance through spatial control of telomeric proteins. Mol Cell
Biol. 27:5898–5909. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cong YS, Wright WE and Shay JW: Human
telomerase and its regulation. Microbiol Mol Biol Rev. 66:407–425.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ducrest AL, Szutorisz H, Lingner J and
Nabholz M: Regulation of the human telomerase reverse transcriptase
gene. Oncogene. 21:541–552. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu L, Li S and Stohr BA: The role of
telomere biology in cancer. Annu Rev Pathol. 8:49–78. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kibe T, Osawa GA, Keegan CE and de Lange
T: Telomere protection by TPP1 is mediated by POT1a and POT1b. Mol
Cell Biol. 30:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xin H, Liu D, Wan M, et al: TPP1 is a
homologue of ciliate TEBP-beta and interacts with POT1 to recruit
telomerase. Nature. 445:559–562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong FL, Batista LF, Freund A, Pech MF,
Venteicher AS and Artandi SE: TPP1 OB-fold domain controls telomere
maintenance by recruiting telomerase to chromosome ends. Cell.
150:481–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tejera AM Stagno, d'Alcontres M,
Thanasoula M, et al: TPP1 is required for TERT recruitment,
telomere elongation during nuclear reprogramming and normal skin
development in mice. Dev Cell. 18:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen LY, Redon S and Lingner J: The human
CST complex is a terminator of telomerase activity. Nature.
488:540–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakashima M, Nandakumar J, Sullivan KD,
Espinosa JM and Cech TR: Inhibition of telomerase recruitment and
cancer cell death. J Biol Chem. 288:33171–33180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Wang W, Hu L, et al:
Telomere-binding protein TPP1 modulates telomere homeostasis and
confers radioresistance to human colorectal cancer cells. PLoS One.
8:e810342013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Augereau A, de T'Kint Roodenbeke C,
Simonet T, et al: Telomeric damage in early stage of chronic
lymphocytic leukemia correlates with shelterin dysregulation.
Blood. 118:1316–1322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Buell JF, Gross TG and Woodle ES:
Malignancy after transplantation. Transplantation. 80(2 Suppl):
S254–S264. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Herman M, Weinstein T, Korzets A, et al:
Effect of cyclosporin A on DNA repair and cancer incidence in
kidney transplant recipients. J Lab Clin Med. 137:14–20. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hojo M, Morimoto T, Maluccio M, et al:
Cyclosporine induces cancer progression by a cell-autonomous
mechanism. Nature. 397:530–534. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shihab FS, Bennett WM, Isaac J, Yi H and
Andoh TF: Nitric oxide modulates vascular endothelial growth factor
and receptors in chronic cyclosporine nephrotoxicity. Kidney Int.
63:522–533. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koehl GE, Andrassy J, Guba M, et al:
Rapamycin protects allografts from rejection while simultaneously
attacking tumors in immunosuppressed mice. Transplantation.
77:1319–1326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dharnidharka VR, Ho PL, Stablein DM,
Harmon WE and Tejani AH: Mycophenolate, tacrolimus and
post-transplant lymphoproliferative disorder: A report of the North
American Pediatric Renal Transplant Cooperative Study. Pediatr
Transplant. 6:396–399. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ohsugi Y, Suzuki S and Takagaki Y:
Antitumor and immunosuppressive effects of mycophenolic acid
derivatives. Cancer Res. 36:2923–2927. 1976.PubMed/NCBI
|
|
46
|
Carter SB, Franklin TJ, Jones DF, et al:
Mycophenolic acid: an anti-cancer compound with unusual properties.
Nature. 223:848–850. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Engl T, Makarević J, Relja B, et al:
Mycophenolate mofetil modulates adhesion receptors of the beta1
integrin family on tumor cells: Impact on tumor recurrence and
malignancy. BMC Cancer. 5:42005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leckel K, Beecken WD, Jonas D, et al: The
immunosuppressive drug mycophenolate mofetil impairs the adhesion
capacity of gastrointestinal tumour cells. Clin Exp Immunol.
134:238–245. 2003. View Article : Google Scholar : PubMed/NCBI
|
